- Home
- SUPN vs CELC Comparison
SUPN vs CELC Comparison
Compare SUPN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- CELC
- Stock Information
- Founded
- SUPN 2005
- CELC 2011
- Country
- SUPN United States
- CELC United States
- Employees
- SUPN N/A
- CELC N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- SUPN Health Care
- CELC Health Care
- Exchange
- SUPN Nasdaq
- CELC Nasdaq
- Market Cap
- SUPN 2.6B
- CELC 2.8B
- IPO Year
- SUPN 2012
- CELC 2017
- Fundamental
- Price
- SUPN $54.61
- CELC $74.99
- Analyst Decision
- SUPN Strong Buy
- CELC Strong Buy
- Analyst Count
- SUPN 3
- CELC 5
- Target Price
- SUPN $62.67
- CELC $69.40
- AVG Volume (30 Days)
- SUPN 725.2K
- CELC 1.6M
- Earning Date
- SUPN 11-04-2025
- CELC 11-13-2025
- Dividend Yield
- SUPN N/A
- CELC N/A
- EPS Growth
- SUPN 1411.53
- CELC N/A
- EPS
- SUPN 1.14
- CELC N/A
- Revenue
- SUPN $665,125,000.00
- CELC N/A
- Revenue This Year
- SUPN $7.31
- CELC N/A
- Revenue Next Year
- SUPN $21.87
- CELC N/A
- P/E Ratio
- SUPN $46.18
- CELC N/A
- Revenue Growth
- SUPN 5.55
- CELC N/A
- 52 Week Low
- SUPN $29.16
- CELC $7.58
- 52 Week High
- SUPN $53.28
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- SUPN 78.22
- CELC 74.39
- Support Level
- SUPN $49.95
- CELC $64.61
- Resistance Level
- SUPN $52.15
- CELC $73.06
- Average True Range (ATR)
- SUPN 1.36
- CELC 4.48
- MACD
- SUPN 0.30
- CELC 2.49
- Stochastic Oscillator
- SUPN 97.61
- CELC 78.84
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.